Get the Stockscreener App
5.12
2.40%
0.12
After Hours:
5.12
Adaptive Biotechnologies Corp stock is traded at $5.12, with a volume of 1.16M.
It is up +2.40% in the last 24 hours and up +8.94% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
See More
Previous Close:
$5.00
Open:
$4.98
24h Volume:
1.16M
Relative Volume:
0.91
Market Cap:
$755.06M
Revenue:
$170.28M
Net Income/Loss:
$-225.25M
P/E Ratio:
-3.8496
EPS:
-1.33
Net Cash Flow:
$-167.02M
1W Performance:
+20.19%
1M Performance:
+8.94%
6M Performance:
+59.50%
1Y Performance:
-6.06%
1-Day Range:
$4.93
$5.51
1-Week Range:
$3.981
$5.53
52-Week Range:
$2.28
$5.53
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
Investing in Adaptive Biotechnologies Corp (ADPT) might be a great opportunity, but the stock is a bit overvalued - US Post News
Adaptive Biotechnologies Corp (ADPT) may enjoy gains as insiders got busy in the recent days - Knox Daily
Adaptive Biotechnologies Shares Rise After EU Certification for Lymphoid Test clonoSEQ - MarketWatch
Check Out Adaptive Biotechnologies Corp (ADPT)’s Trade Data Rather Than the Analysts’ Views - SETE News
Was there any good news for Adaptive Biotechnologies Corp (ADPT) stock in the last session? - US Post News
Adaptive Biotechnologies Corp (ADPT) gets rating Resumed from JP Morgan - Knox Daily
Federated Hermes Inc. Sells 1,244,445 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Federated Hermes Inc. Has $207,000 Stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Daily Progress: Adaptive Biotechnologies Corp (ADPT) Drop -8.39, Closing at 4.26 - The Dwinnex
The ADPT Stock Puzzle: Unraveling Adaptive Biotechnologies Corp’s Fluctuating Performance - The InvestChronicle
ADPT (Adaptive Biotechnologies) Current Ratio : 3.99 (As of Jun. 2024) - GuruFocus.com
Analysts Set Adaptive Biotechnologies Co. (NASDAQ:ADPT) Target Price at $6.40 - MarketBeat
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Acquired by Massachusetts Financial Services Co. MA - Defense World
Rubric Capital Management LP Acquires 3,500,000 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Down 5.2% - MarketBeat
Insider Selling: Taylor Stacy L, Adaptive Biotechnologies Corp [ADPT] SVP and General Counsel divested 26,922 shares – Knox Daily - Knox Daily
This trade activity should not be overlooked: Adaptive Biotechnologies Corp (ADPT) - SETE News
Principal Financial Group Inc. Cuts Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
How did Adaptive Biotechnologies Corp (ADPT) fare last session? - US Post News
Los Angeles Capital Management LLC Boosts Stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Latest Insider moments: Taylor Stacy L, Adaptive Biotechnologies Corp [ADPT] SVP and General Counsel sold 26,922 shares – Knox Daily - Knox Daily
Analyzing Ratios: Adaptive Biotechnologies Corp (ADPT)’s Financial Story Unveiled - The Dwinnex
Caprock Group LLC Sells 12,516 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Trading 8.4% Higher - MarketBeat
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Down 3.2% - MarketBeat
A company insider recently sold 26,922 shares of Adaptive Biotechnologies Corp [ADPT]. Should You Sale? - Knox Daily
A closer look at Adaptive Biotechnologies Corp (ADPT) is warranted - US Post News
Adaptive Biotechnologies Corp [ADPT] Insider Taylor Stacy L sells 26,922 Shares – Insider Selling Alert - Knox Daily
You might want to take a look at Adaptive Biotechnologies Corp (ADPT) now - SETE News
Adversity is less terrifying than hope: Adaptive Biotechnologies Corp (ADPT) - SETE News
Adaptive Biotechnologies Corp (ADPT)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Are Adaptive Biotechnologies Corp (ADPT) shares a good deal now? - US Post News
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Sees Significant Drop in Short Interest - MarketBeat
SVP and General Counsel Taylor Stacy L sold 26,922 shares of Adaptive Biotechnologies Corp [ADPT] - Knox Daily
Adaptive Biotechnologies' clonoSEQ gains EU IVDR certification - Investing.com
Adaptive Announces IVDR Certification for clonoSEQ® in European Union - Yahoo Finance
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Bought by Legato Capital Management LLC - MarketBeat
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Holdings Lifted by Nisa Investment Advisors LLC - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
A significant driver of top-line growth: Adaptive Biotechnologies Corp (ADPT) - SETE News
Market Watch Highlights: Adaptive Biotechnologies Corp (ADPT) Ends on an Downturn Note at 4.81 - The Dwinnex
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Adaptive Biotechnologies Corp (ADPT) receives an Overweight rating from JP Morgan - Knox Daily
Adaptive Biotechnologies Corp (ADPT)’s stock price in review: A technical analysis - US Post News
Behind Adaptive Biotechnologies Corp’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
Adaptive Biotechnologies Corp [ADPT] Shares Fall Approximately -28.42% Over the Year - Knox Daily
Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - Yahoo Finance
Insider’s View: Deciphering Adaptive Biotechnologies Corp (ADPT)’s Financial Health Through Ratios - The Dwinnex
Adaptive Biotechnologies (STU:1HM) 14-Day RSI : 60.79 (As of Aug. 20, 2024) - GuruFocus.com
Adaptive Biotechnologies (STU:1HM) GF Value : €6.54 (As of Aug. 20, 2024) - GuruFocus.com
ADPT (Adaptive Biotechnologies) Liabilities-to-Assets : 0.59 (As of Jun. 2024) - GuruFocus.com
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):